FDA Approves Generic Diagnostic Agent for Prostate Cancer Imaging

The U.S. Food and Drug Administration has approved an abbreviated new drug application for a generic radiodiagnostic agent, gallium Ga 68 gozetotide injection. This approval expands access to a crucial PET imaging tool used to identify prostate-specific membrane antigen-positive lesions in individuals with prostate cancer.